Syndax Pharmaceuticals, Inc.
A biopharmaceutical company developing cancer treatments. They develop oral drugs such as entinostat, which acts directly on both cancer cells and immune cells to enhance the immune response to cancer cells, and monoclonal antibodies. They are expected to activate immune cells by colony-stimulating factors to treat breast cancer, leukemia, etc. They are based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | Massachusetts |
Employees | 184 |
Founded | 2005 |
Financials | |
|---|---|
Market Capitalization | 2.00B |
Revenue | |
Operating Income | -263.45M |
Operating Margin | |
Net Income | -240.63M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 5159 / 5373 |
Sector : Healthcare | 1067 / 1144 |
Industry : Biotechnology | 592 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 1955 / 5565 |
Sector : Healthcare | 234 / 1182 |
Industry : Biotechnology | 80 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 5150 / 5436 |
Sector : Healthcare | 1081 / 1164 |
Industry : Biotechnology | 608 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 3607 / 5330 |
Sector : Healthcare | 478 / 1174 |
Industry : Biotechnology | 147 / 667 |